Nicolas Marincek1, Piotr Radojewski2, Rebecca A Dumont3, Philippe Brunner1, Jan Müller-Brand1, Helmut R Maecke4, Matthias Briel5, Martin A Walter6. 1. Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland. 2. Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland. 3. Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland Department of Radiology, David Geffen School of Medicine, UCLA, Los Angeles, California. 4. Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland. 5. Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; and. 6. Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland Institute of Nuclear Medicine, University Hospital Bern, Bern, Switzerland Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California m.a.walter@gmx.net.
Abstract
UNLABELLED: Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients. METHODS: Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. RESULTS: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n = 34; P = 0.019) were associated with longer survival. CONCLUSION: (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.
UNLABELLED: Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningiomapatients. METHODS:Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. RESULTS: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n = 34; P = 0.019) were associated with longer survival. CONCLUSION: (90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.
Authors: Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn Journal: Neuro Oncol Date: 2016-02-09 Impact factor: 12.300
Authors: Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Asma Bashir; Mark Bitsch Vestergaard; Tina Binderup; Helle Broholm; Lisbeth Marner; Morten Ziebell; Kåre Fugleholm; Tiit Mathiesen; Andreas Kjær; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2020-03-13 Impact factor: 9.236
Authors: Robin A Buerki; Craig M Horbinski; Timothy Kruser; Peleg M Horowitz; Charles David James; Rimas V Lukas Journal: Future Oncol Date: 2018-08-07 Impact factor: 3.404
Authors: Frank A E Kruyt; Rob J M Groen; Bianca M Dijkstra; Marion de Jong; Marcus C M Stroet; Fritz Andreae; Sebastiaan E Dulfer; Marieke Everts; Schelto Kruijff; Julie Nonnekens; Wilfred F A den Dunnen Journal: J Neurooncol Date: 2021-03-26 Impact factor: 4.130